ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This is a multicenter phase IIb study to evaluate the efficacy and tolerability of
ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with metastatic
castration-resistant prostate cancer, suitable for treatment with a taxane.